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Among 563 strains of Haemophilus influenzae from
young children in Hong Kong, 5 (0.9%) had decreased sus-
ceptibility to quinolones. The five strains had a Ser-84-Lys or
Asp-88-Asn substitution in GyrA. Pulsed-field gel elec-
trophoresis showed that the isolates are genetically diverse. 
A
lthough fluoroquinolone-resistant Haemophilus
influenzae were reported a decade ago (1), this resist-
ance phenotype has remained rare (2). In general, resist-
ance to fluoroquinolone is chromosome-mediated,
involves mutations in one or both target genes encoding
DNAgyrase and topoisomerase IV, and tends to develop in
a stepwise manner. The MICs of various antimicrobial
agents for such mutant strains increases with each addi-
tional mutation in the target sites. In H. influenzae, high-
level resistance to the fluoroquinolones generally occurs in
the presence of mutations involving both gyrA and parC.
In  H. influenzae,  gyrA is the primary target for fluoro-
quinolones because gyrA mutations have generally arisen
before  parC mutations in resistant clinical isolates (2).
First-step gyrA mutants showed reduced susceptibility to
fluoroquinolones, but the MICs remain in the susceptible
range. Resistance mechanisms in these isolates will be
undetected if the fluoroquinolones’ susceptibility was
determined and the results interpreted according to the cur-
rent breakpoints. We assessed the susceptibility of H.
influenzae nasopharyngeal isolates, obtained from children
throughout Hong Kong, to nalidixic acid and levofloxacin. 
The Study
During the study period (December 1999 to June 2000),
a total of 1,978 children, 2 to 6 years of age, were recruit-
ed from 79 daycare centers or kindergartens throughout
Hong Kong. Details of the study population and the find-
ings in relation to Streptococcus pneumoniae have been
described (3). In brief, nasopharyngeal swab specimens
were obtained from a predetermined number of children
in each daycare center or kindergarten. On average,
25 children (standard deviation [SD] 11) from each insti-
tute were examined. For isolation of H. influenzae, a
previously described selective medium (chocolate gono-
coccal [GC] agar base with sheep blood, supplemented
with 1% yeast autolysate and vancomycin 5 µg/mL,
bacitracin   300 µg/mL, and clindamycin 1 µg/mL) was
used for swab inoculation (4). Plates to which samples
were added were incubated in 5% CO2 for  <48 h. All
isolates were identified by colony morphologic features,
Gram stain, and requirement for both X and V factors. 
The MICs of nalidixic acid, levofloxacin, ampicillin,
and azithromycin were determined by the MIC microbroth
dilution method with an in-house Haemophilus test medi-
um broth (5) and interpreted according to National
Committee for Clinical Laboratory Standards (NCCLS)
guidelines (6). Quality control strains (H. influenzaeATCC
49247 and ATCC 49766) were included with each run. All
isolates were tested for the production of β-lactamase by
nitrocephin paper disks (Cefinase, BBL, Becton Dickinson
Microbiology Systems, Franklin Lakes, NJ). 
The subset of isolates with reduced susceptibility to
levofloxacin was examined further by pulsed-field gel
electrophoresis (PFGE) using SmaI for DNAdigestion (7),
and the results were interpreted according to Tenover et al.
(8). The isolates were also examined for gyrA and parC
mutations by using primers and methods described (7). 
The median age (interquartile range) for these 1,978
children was 5.3 years (4.3−5.3 years); the mean age was
5 years. Approximately half of the children were boys
(52.7%). Sixty-three percent of surveyed children had sib-
lings <12 years of age; 277 (14%) of the children had an
overcrowded living environment (living space <5.5
m2/person, according to the guideline of the Hong Kong
Housing Authority). At the time of the survey, 103 (5.2%)
of the 1,978 children were reported to be taking antimicro-
bial agents. In the 3 months before the study, 1,535
(77.6%) had visited their family doctor, and 63 (3.2%) had
been hospitalized. 
Overall, the carriage rate of H. influenzae was 28.5%
(range 17%–42.1%). The MICs of nalidixic acid and lev-
ofloxacin for all isolates are shown in Table 1. Five (0.9%)
isolates were resistant to nalidixic acid with MICs of 64
µg/mL to 128 µg/mL. The levofloxacin MICs of the same
five isolates were 0.125 µg/mL, which is higher than the
MICs (range 0.0019–0.06 µg/mL; mode 0.015) of the
same antimicrobial drug for the nalidixic acid–sensitive
isolates. Of the 563 isolates, 158 (28.1%) were β-lacta-
mase–positive strains and thus were resistant to ampicillin.
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Region, China All isolates were susceptible to azithromycin with an
MIC50 of 1 µg/mL and an MIC90 of 2 µg/mL.
None of the five children with nalidixic acid–resistant
H. influenzae had been previously hospitalized. All five
children had been treated with antimicrobial drugs in the
previous 3 months, and two were taking antimicrobial
drugs at the time samples were obtained. The specific
antimicrobial agents were unknown. Two children had
asthma, and the remaining three children had no underly-
ing diseases. 
The quinolone resistance–determining regions of gyrA
and parC for the eight isolates with resistance or reduced
susceptibility to nalidixic acid (MIC > 4 µg/mL) or lev-
ofloxacin (MIC >0.06 µg/mL) were sequenced (Table 2).
A Ser-84-Lys or Asp-88-Asn substitution was found in
GyrA in all five isolates with resistance to nalidixic acid.
No substitutions occurred in ParC. No amino acid substi-
tution was found in either GyrA or ParC in the three iso-
lates with reduced susceptibility to nalidixic acid (MIC
4–8 µg/mL). In pulsed-field gel electrophoresis analysis,
the five nalidixic acid–resistant strains had distinct pat-
terns and were unrelated. 
Conclusions
Our data have shown, for the first time, resistance to
quinolones among H. influenzae isolates in children. The
finding is of clinical and public health concern, particular-
ly in regions like Hong Kong where levels of antimicrobial
resistance among respiratory pathogens are already high,
and fluoroquinolone resistance in S. pneumoniae is emerg-
ing (9,10). The finding is also unexpected because fluoro-
quinolones are not approved for use among children in
Hong Kong; such agents are not approved for children in
the rest of the world as well. We believe that three poten-
tial explanations may account for the detection of fluoro-
quinolone resistance among children. First, nalidixic acid
is approved to treat pediatric infections and is widely used
in Hong Kong for outpatient and inpatient treatment of uri-
nary tract infections and, occasionally, to treat shigellosis
in children. In the Queen Mary Hospital, for instance, 13.5
and 10.0 defined daily doses per 100 pediatric admissions
of nalidixic acid were used in 1999 and 2000, respectively
(1 defined daily dose of nalidixic acid equals 4 g). In chil-
dren, carriage of H. influenzae is common. The identified
first-step mutant might be selected de novo when isolates
colonizing the nasopharynx are exposed to the selection
pressure from nalidixic acid. Second, use of fluoro-
quinolones in food animals is common in many Asian
countries (2). Children could be exposed to residues of flu-
oroquinolones by consuming meat or dairy products from
food animal previously fed antimicrobial agents from this
group. At present, we do not know how exposure to
residues of antimicrobial agents in food contributes to
resistance (11). Presumably, the level of exposure from
dietary source would be low. In the nasopharynx, the level
of quinolone is approximately half the level it would be in
the blood (12). If food levels of quinolones are controlled
to within the acceptable minimum residual levels, the con-
tribution from this route of potential exposure should be
minimal. Finally, transmission from adults to children
might have occurred in household settings. Although
adult-to-child transmission appears to be uncommon,
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Quinolone-resistant H. influenzae in Childrentransmission of H. influenzae from child to adult or
among siblings in household setting is well known (13).
We do not have any comparative figures for isolates from
adults. If adults are a source of the quinolone-resistant iso-
lates, one would expect greater resistance rates in adults
than children.
Detection of H. influenzae isolates from children with a
first-step mutation in gyrA affects whether the fluoro-
quinolones should be approved for pediatric indications
(14). So far, the main concerns among the scientific com-
munity have centered on the selection of fluoroquinolone-
resistant pneumococci. Unlike adults, children frequently
carry pneumococci in the nasopharynx and at high density.
If the fluoroquinolones are used widely in children to treat
infections such as salmonellosis, recurrent otitis media,
and urinary tract infections, the selection of mutational
resistance to the fluoroquinolones will likely occur more
rapidly among children than among adults. Once resist-
ance is selected, fluoroquinolone-resistant strains could
disseminate rapidly and widely in the community by cross-
transmissions in groups attending daycare centers and
schools. Our finding thus highlights the need to monitor
resistance not only among the infecting organisms being
treated, but also the need to monitor colonizing bacteria in
the same or other body sites that were also exposed to
antimicrobial agents. 
Our data have shown a low incidence (0.9%) of
decreased levofloxacin susceptibility due to gyrA muta-
tions among strains of H. influenzae isolated from children
in Hong Kong. This finding warrants public health con-
cern. Given that the fluoroquinolones might be increasing-
ly used as a rescue therapy for certain pediatric infections
that do not respond to other agents, surveillance of this
type of resistance mechanism must be enhanced. In this
regard, we have found that resistance to nalidixic acid
(MIC  ≥  64  µg/mL) or reduced susceptibility to lev-
ofloxacin (MIC ≥ 0.125 good µg/mL) might be useful sur-
rogates. After we submitted this manuscript, similar
observations on the laboratory detection of deceased sus-
ceptibility due to gyrA and parC mutations were reported
(15); thus, our findings were corroborated.  
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